mDCs manufactured using GM-CSF and IL-4 primed with OK-432 for clinical use expressed the HLA−ABC+DR+CD40+CD80+CD86+CD197+ phenotype, harboring bioactive functions that could be useful in providing personalized vaccines for cancer immunotherapy [32]. This evidence concerns the gene CCR7 and cancer.